

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

***APPLICATION NUMBER:***

**213591Orig1s000**

***Trade Name:*** Tabrecta, 150 mg and 200 mg tablets

***Generic or Proper Name:*** (capmatinib)

***Sponsor:*** Novartis Pharmaceuticals Corporation

***Approval Date:*** May 6, 2020

***Indication:*** A kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 213591Orig1s000

### CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                                                                                                                                                                                                                                                                                     |          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| <b>Approval Letter</b>                                                                                                                                                                                                                                                                                              | <b>X</b> |
| <b>Other Action Letters</b>                                                                                                                                                                                                                                                                                         |          |
| <b>Labeling</b>                                                                                                                                                                                                                                                                                                     | <b>X</b> |
| <b>REMS</b>                                                                                                                                                                                                                                                                                                         |          |
| <b>Officer/Employee List</b>                                                                                                                                                                                                                                                                                        | <b>X</b> |
| <b>Multidiscipline Review(s)</b> <ul style="list-style-type: none"><li>• <b>Summary Review</b></li><li>• <b>Office Director</b></li><li>• <b>Cross Discipline Team Leader</b></li><li>• <b>Clinical</b></li><li>• <b>Non-Clinical</b></li><li>• <b>Statistical</b></li><li>• <b>Clinical Pharmacology</b></li></ul> | <b>X</b> |
| <b>Product Quality Review(s)</b>                                                                                                                                                                                                                                                                                    | <b>X</b> |
| <b>Clinical Microbiology / Virology Review(s)</b>                                                                                                                                                                                                                                                                   |          |
| <b>Other Reviews</b>                                                                                                                                                                                                                                                                                                | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>                                                                                                                                                                                                                                                                | <b>X</b> |
| <b>Proprietary Name Review(s)</b>                                                                                                                                                                                                                                                                                   | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>                                                                                                                                                                                                                                                                    | <b>X</b> |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**213591Orig1s000**

**APPROVAL LETTER**



NDA 213591

**ACCELERATED APPROVAL**

Novartis Pharmaceuticals Corporation  
Attention: Reena Nadpara, Pharm.D.  
Senior Global Program Regulatory Manager  
Regulatory Affairs, Oncology  
One Health Plaza  
East Hanover, NJ 07936

Dear Dr. Nadpara,

Please refer to your new drug application (NDA) dated December 10, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tabrecta (capmatinib), 150 mg and 200 mg tablets.

This new drug application provides for the use of Tabrecta (capmatinib), 150 mg and 200 mg tablets for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 314.500), effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced accelerated approval regulations.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, text for the Patient Package Insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, submitted on April 17, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 213591.**” Approval of this submission by FDA is not required before the labeling is used.

### **MARKET PACKAGE**

Please submit one market package of the drug product when it is available to the following address:

Kelie Reece, Ph.D.  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 2383  
10903 New Hampshire Avenue  
Silver Spring, Maryland  
Use zip code **20903** if shipping via United States Postal Service (USPS).  
Use zip code **20993** if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).

### **ADVISORY COMMITTEE**

Your application for Tabrecta (capmatinib) was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues; and the application did not raise significant public health questions on the role of the drug in the diagnosis, cure, mitigation, treatment, or prevention of a disease.

### **ACCELERATED APPROVAL REQUIREMENTS**

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further adequate and well-controlled clinical trials to verify and describe clinical benefit. You are required to conduct such clinical trials with due diligence. If postmarketing clinical trials fail to verify clinical benefit or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530, withdraw this approval. We remind you of your postmarketing requirement specified in your submission dated April 22 and April 29, 2020. This requirement, along with required completion dates, is listed below.

U.S. Food and Drug Administration  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

3828-1 Submit the final reports including datasets from clinical studies to confirm and further characterize the clinical benefit of capmatinib for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping who are treatment-naïve and who have previously received platinum-based chemotherapy, by providing a more precise estimation of the blinded independent central review-assessed overall response rate and duration of response. This report will contain data from NSCLC patients whose tumors have a mutation that leads to MET exon 14 skipping; data from at least 60 patients who are treatment naïve, after all responders have been followed for at least 12 months from the date of initial response (or until disease progression, whichever comes first); and from at least 85 patients who have been treated with platinum-based therapy, after all responders have been followed for at least 6 months from the date of initial response (or until disease progression, whichever comes first).

Final Protocol Submission: 03/2019 (completed)  
Trial Completion: 08/2021  
Final Report Submission: 02/2022

Submit clinical protocols to your IND 124033 for this product. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each requirement in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each trial.

Submit final reports to this NDA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated “**Subpart H Postmarketing Requirement(s).**”

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has orphan drug designation, you are exempt from this requirement.

## **PROMOTIONAL MATERIALS**

Under 21 CFR 314.550, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at 301-796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 314.550, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated references, and approved Prescribing Information (PI)/Medication Guide/Patient Package Insert (as applicable).

Send each submission directly to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotions (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit promotional materials for accelerated approval products electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>3</sup> When final, this guidance will represent the FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

### **MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at [FDA.gov](http://FDA.gov).<sup>4</sup>

### **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Kelie Reece, Regulatory Health Project Manager, at 240-402-6397.

Sincerely,

*{See appended electronic signature page}*

Marc Theoret, M.D.  
Acting Deputy Director  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

#### **ENCLOSURES:**

- Content of Labeling
  - o Prescribing Information
  - o Patient Package Insert
- Carton and Container Labeling

---

<sup>4</sup> <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

MARC R THEORET  
05/06/2020 12:48:39 PM